Login Register Cart 0
Mini-Review Article

程序死亡配体1 (PD-L1)状态的免疫组织化学和评分算法

卷 21, 期 13, 2020

页: [1286 - 1292] 页: 7

弟呕挨: 10.2174/1389450121666200123124642

价格: $65

摘要

免疫组织化学检测程序性死亡配体1 (PD-L1)蛋白是目前唯一被批准的用于预测靶向PD1/PDL1轴的药物反应的试验。由于几种试剂在不同的免疫染色平台上被用作不同药物的伴生诊断，因此该测试的作用存在争议。此外，PD-L1免疫组织化学的不同评分系统已经应用于单药的注册研究。本文综述了与PD-L1免疫组化检测相关的各种问题。我们讨论了PD-L1免疫组化的优点和缺陷等目前尚未解决的问题;选择最好的试剂和最好的评分系统。最后，我们回顾了目前PD-L1免疫组织化学在免疫检查点抑制剂临床试验中的作用。

关键词: 癌症，免疫治疗，PD-L1，免疫组织化学，评分系统，算法

« Previous Next »
图形摘要

[1]
Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol 2018; 18(3): 153-67.
[http://dx.doi.org/10.1038/nri.2017.108] [PMID: 28990585]
[2]
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12(4): 252-64.
[http://dx.doi.org/10.1038/nrc3239] [PMID: 22437870]
[3]
Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 2015; 14(4): 847-56.
[http://dx.doi.org/10.1158/1535-7163.MCT-14-0983] [PMID: 25695955]
[4]
Morgensztern D. KEYNOTE-042 and the role for single agent pembrolizumab in patients with PD-L1 tumor proportion score 1-49. J Thorac Dis 2019; 11(Suppl. 15): S1963-5.
[http://dx.doi.org/10.21037/jtd.2019.07.80] [PMID: 31632798]
[5]
Shafique MR, Robinson LA, Antonia S. Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer. Cancer Manag Res 2018; 10: 931-40.
[http://dx.doi.org/10.2147/CMAR.S148009] [PMID: 29760563]
[6]
Solinas C, Pusole G, Demurtas L, et al. Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications. Crit Rev Oncol Hematol 2017; 110: 106-16.
[http://dx.doi.org/10.1016/j.critrevonc.2016.11.016] [PMID: 28109400]
[7]
Pérottet J, Le Goff E, Legoupil D, et al. PD-L1 copy number variation does not correlate with pd-l1 expression or response to anti-pd-1 immunotherapy in patients with advanced melanomas. Appl Immunohistochem Mol Morphol IN PRESS
[http://dx.doi.org/10.1097/PAI.0000000000000712] [PMID: 31335487]
[8]
Erlmeier F, Weichert W, Schrader AJ, et al. Prognostic impact of PD-1 and its ligands in renal cell carcinoma. Med Oncol 2017; 34(6): 99.
[http://dx.doi.org/10.1007/s12032-017-0961-y] [PMID: 28432616]
[9]
Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med 2018; 378(22): 2093-104.
[http://dx.doi.org/10.1056/NEJMoa1801946] [PMID: 29658845]
[10]
Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366(26): 2455-65.
[http://dx.doi.org/10.1056/NEJMoa1200694] [PMID: 22658128]
[11]
Straub M, Drecoll E, Pfarr N, et al. CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity. Oncotarget 2016; 7(11): 12024-34.
[http://dx.doi.org/10.18632/oncotarget.7593] [PMID: 26918453]
[12]
Barlesi F, Vansteenkiste J, Spigel D, et al. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. Lancet Oncol 2018; 19(11): 1468-79.
[http://dx.doi.org/10.1016/S1470-2045(18)30673-9] [PMID: 30262187]
[13]
Dirix LY, Takacs I, Jerusalem G, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res Treat 2018; 167(3): 671-86.
[http://dx.doi.org/10.1007/s10549-017-4537-5] [PMID: 29063313]
[14]
Hirsch FR, McElhinny A, Stanforth D, et al. PD-L1 Immunohistochemistry assays for lung cancer: results from phase 1 of the Blueprint PD-L1 IHC assay comparison project. J Thorac Oncol 2017; 12(2): 208-22.
[http://dx.doi.org/10.1016/j.jtho.2016.11.2228] [PMID: 27913228]
[15]
Ratcliffe MJ, Sharpe A, Midha A, et al. Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cutoffs in non-small cell lung cancer. Clin Cancer Res 2017; 23(14): 3585-91.
[http://dx.doi.org/10.1158/1078-0432.CCR-16-2375] [PMID: 28073845]
[16]
Giunchi F, Degiovanni A, Daddi N, et al. Fading with time of pd-l1 immunoreactivity in non-small cells lung cancer tissues: a methodological study. Appl Immunohistochem Mol Morphol 2018; 26(7): 489-94.
[http://dx.doi.org/10.1097/PAI.0000000000000458] [PMID: 27801735]
[17]
Capizzi E, Ricci C, Giunchi F, et al. Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer. Lung Cancer 2018; 126: 9-14.
[http://dx.doi.org/10.1016/j.lungcan.2018.10.017] [PMID: 30527198]
[18]
Skov BG, Skov T. Paired comparison of PD-L1 expression on cytologic and histologic specimens from malignancies in the lung assessed with PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx. Appl Immunohistochem Mol Morphol 2017; 25(7): 453-9.
[http://dx.doi.org/10.1097/PAI.0000000000000540] [PMID: 28549039]
[19]
She L, Hu H, Liao M, et al. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater. Lung Cancer 2019; 138: 88-94.
[http://dx.doi.org/10.1016/j.lungcan.2019.10.017] [PMID: 31655368]
[20]
Kulangara K, Zhang N, Corigliano E, et al. Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer. Arch Pathol Lab Med 2019; 143(3): 330-7.
[http://dx.doi.org/10.5858/arpa.2018-0043-OA] [PMID: 30028179]
[21]
Bellmunt J, Mullane SA, Werner L, et al. Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol 2015; 26(4): 812-7.
[http://dx.doi.org/10.1093/annonc/mdv009] [PMID: 25600565]
[22]
Nakanishi J, Wada Y, Matsumoto K, Azuma M, Kikuchi K, Ueda S. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother 2007; 56(8): 1173-82.
[http://dx.doi.org/10.1007/s00262-006-0266-z] [PMID: 17186290]
[23]
Massard C, Gordon MS, Sharma S, et al. Safety and efficacy of durvalumab (medi4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol 2016; 34(26): 3119-25.
[http://dx.doi.org/10.1200/JCO.2016.67.9761] [PMID: 27269937]
[24]
Plimack ER, Bellmunt J, Gupta S, et al. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol 2017; 18(2): 212-20.
[http://dx.doi.org/10.1016/S1470-2045(17)30007-4] [PMID: 28081914]
[25]
Hodgson A, Slodkowska E, Jungbluth A, et al. PD-L1 immunohistochemistry assay concordance in urothelial carcinoma of the bladder and hypopharyngeal squamous cell carcinoma. Am J Surg Pathol 2018; 42(8): 1059-66.
[http://dx.doi.org/10.1097/PAS.0000000000001084] [PMID: 29750666]
[26]
Rijnders M, van der Veldt AAM, Zuiverloon TCM, et al. PD-L1 Antibody Comparison in Urothelial Carcinoma. Eur Urol 2019; 75(3): 538-40.
[http://dx.doi.org/10.1016/j.eururo.2018.11.002] [PMID: 30497882]
[27]
Reis H, Serrette R, Posada J, et al. PD-L1 expression in urothelial carcinoma with predominant or pure variant histology: concordance among 3 commonly used and commercially available antibodies. Am J Surg Pathol 2019; 43(7): 920-7.
[http://dx.doi.org/10.1097/PAS.0000000000001264] [PMID: 31135485]
[28]
Powles T, Durán I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2018; 391(10122): 748-57.
[http://dx.doi.org/10.1016/S0140-6736(17)33297-X] [PMID: 29268948]
[29]
Choueiri TK, Fay AP, Gray KP, et al. PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol 2014; 25(11): 2178-84.
[http://dx.doi.org/10.1093/annonc/mdu445] [PMID: 25193987]
[30]
Choueiri TK, Figueroa DJ, Fay AP, et al. Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial. Clin Cancer Res 2015; 21(5): 1071-7.
[http://dx.doi.org/10.1158/1078-0432.CCR-14-1993] [PMID: 25538263]
[31]
McDermott DF, Sosman JA, Sznol M, et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase ia study. J Clin Oncol 2016; 34(8): 833-42.
[http://dx.doi.org/10.1200/JCO.2015.63.7421] [PMID: 26755520]
[32]
Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol 2019; 20(10): 1370-85.
[http://dx.doi.org/10.1016/S1470-2045(19)30413-9] [PMID: 31427204]
[33]
Cocks M, Taheri D, Ball MW, et al. Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort. Hum Pathol 2017; 59: 55-61.
[http://dx.doi.org/10.1016/j.humpath.2016.09.003] [PMID: 27663086]

Rights & Permissions Print Cite
Article Metrics
20
© 2024 Bentham Science Publishers | Privacy Policy